Mechanism of action of estrogen on intramembranous bone formation

Regulation of osteoblast differentiation and activity

Russell T. Turner, Peggy Backup, Pamela J. Sherman, Esther Hill, Glenda L. Evans, Thomas C. Spelsberg

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Dynamic bone histomorphometry, [3H]thymidine radioautography, and Northern analysis for bone matrix proteins and insulin-like growth factor-I (IGF-I) were performed in calvariae of ovariectomized (OVX) and estrogen-treated OVX rats. Treatment of OVX rats with diethylstilbestrol (DES) for 2 weeks reduced the periosteal mineral apposition rate, osteoblast number, and osteoblast size in calvarial periosteum. DES treatment also reduced the number of preosteoblasts in the S phase of the cell cycle, suggesting that the decrease in osteoblast number was due in part to inhibition of proliferation of osteoprogenitor cells. One week after ovariectomy, there were small increases in mRNA levels for pre pro-α2 (I) subunit of type I collagen (collagen), ostcocalein, and osteonectin and a large increase in the mRNA level for IGF-I. DES treatment resulted in rapid decreases (3 h) in the mRNA levels for osteonectin, osteocalcin, and IGF-I. In contrast, mRNA levels for collagen were virtually unchanged after short term DES treatment. Uterus and liver served as positive and negative control tissues, respectively, for the effects of DES on IGF-I mRNA levels in OVX rats; mRNA levels were increased in uterus and decreased in liver after hormone treatment. We conclude from these studies that estrogen reduces periosteal bone formation by inhibiting both the differentiation and activity of osteoblasts. Furthermore, down-regulation of mRNA levels for IGF-I and bone matrix proteins precedes the changes in dynamic bone histomorphometry.

Original languageEnglish (US)
Pages (from-to)883-889
Number of pages7
JournalEndocrinology
Volume131
Issue number2
StatePublished - Aug 1992

Fingerprint

Osteoblasts
Osteogenesis
Diethylstilbestrol
Estrogens
Insulin-Like Growth Factor I
Messenger RNA
Osteonectin
Bone Matrix
Uterus
Collagen
Bone and Bones
Periosteum
Liver
Osteocalcin
Ovariectomy
Collagen Type I
Autoradiography
S Phase
Skull
Thymidine

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Turner, R. T., Backup, P., Sherman, P. J., Hill, E., Evans, G. L., & Spelsberg, T. C. (1992). Mechanism of action of estrogen on intramembranous bone formation: Regulation of osteoblast differentiation and activity. Endocrinology, 131(2), 883-889.

Mechanism of action of estrogen on intramembranous bone formation : Regulation of osteoblast differentiation and activity. / Turner, Russell T.; Backup, Peggy; Sherman, Pamela J.; Hill, Esther; Evans, Glenda L.; Spelsberg, Thomas C.

In: Endocrinology, Vol. 131, No. 2, 08.1992, p. 883-889.

Research output: Contribution to journalArticle

Turner, RT, Backup, P, Sherman, PJ, Hill, E, Evans, GL & Spelsberg, TC 1992, 'Mechanism of action of estrogen on intramembranous bone formation: Regulation of osteoblast differentiation and activity', Endocrinology, vol. 131, no. 2, pp. 883-889.
Turner RT, Backup P, Sherman PJ, Hill E, Evans GL, Spelsberg TC. Mechanism of action of estrogen on intramembranous bone formation: Regulation of osteoblast differentiation and activity. Endocrinology. 1992 Aug;131(2):883-889.
Turner, Russell T. ; Backup, Peggy ; Sherman, Pamela J. ; Hill, Esther ; Evans, Glenda L. ; Spelsberg, Thomas C. / Mechanism of action of estrogen on intramembranous bone formation : Regulation of osteoblast differentiation and activity. In: Endocrinology. 1992 ; Vol. 131, No. 2. pp. 883-889.
@article{aa1af66c97e340b3a275cfc020e4abe0,
title = "Mechanism of action of estrogen on intramembranous bone formation: Regulation of osteoblast differentiation and activity",
abstract = "Dynamic bone histomorphometry, [3H]thymidine radioautography, and Northern analysis for bone matrix proteins and insulin-like growth factor-I (IGF-I) were performed in calvariae of ovariectomized (OVX) and estrogen-treated OVX rats. Treatment of OVX rats with diethylstilbestrol (DES) for 2 weeks reduced the periosteal mineral apposition rate, osteoblast number, and osteoblast size in calvarial periosteum. DES treatment also reduced the number of preosteoblasts in the S phase of the cell cycle, suggesting that the decrease in osteoblast number was due in part to inhibition of proliferation of osteoprogenitor cells. One week after ovariectomy, there were small increases in mRNA levels for pre pro-α2 (I) subunit of type I collagen (collagen), ostcocalein, and osteonectin and a large increase in the mRNA level for IGF-I. DES treatment resulted in rapid decreases (3 h) in the mRNA levels for osteonectin, osteocalcin, and IGF-I. In contrast, mRNA levels for collagen were virtually unchanged after short term DES treatment. Uterus and liver served as positive and negative control tissues, respectively, for the effects of DES on IGF-I mRNA levels in OVX rats; mRNA levels were increased in uterus and decreased in liver after hormone treatment. We conclude from these studies that estrogen reduces periosteal bone formation by inhibiting both the differentiation and activity of osteoblasts. Furthermore, down-regulation of mRNA levels for IGF-I and bone matrix proteins precedes the changes in dynamic bone histomorphometry.",
author = "Turner, {Russell T.} and Peggy Backup and Sherman, {Pamela J.} and Esther Hill and Evans, {Glenda L.} and Spelsberg, {Thomas C.}",
year = "1992",
month = "8",
language = "English (US)",
volume = "131",
pages = "883--889",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Mechanism of action of estrogen on intramembranous bone formation

T2 - Regulation of osteoblast differentiation and activity

AU - Turner, Russell T.

AU - Backup, Peggy

AU - Sherman, Pamela J.

AU - Hill, Esther

AU - Evans, Glenda L.

AU - Spelsberg, Thomas C.

PY - 1992/8

Y1 - 1992/8

N2 - Dynamic bone histomorphometry, [3H]thymidine radioautography, and Northern analysis for bone matrix proteins and insulin-like growth factor-I (IGF-I) were performed in calvariae of ovariectomized (OVX) and estrogen-treated OVX rats. Treatment of OVX rats with diethylstilbestrol (DES) for 2 weeks reduced the periosteal mineral apposition rate, osteoblast number, and osteoblast size in calvarial periosteum. DES treatment also reduced the number of preosteoblasts in the S phase of the cell cycle, suggesting that the decrease in osteoblast number was due in part to inhibition of proliferation of osteoprogenitor cells. One week after ovariectomy, there were small increases in mRNA levels for pre pro-α2 (I) subunit of type I collagen (collagen), ostcocalein, and osteonectin and a large increase in the mRNA level for IGF-I. DES treatment resulted in rapid decreases (3 h) in the mRNA levels for osteonectin, osteocalcin, and IGF-I. In contrast, mRNA levels for collagen were virtually unchanged after short term DES treatment. Uterus and liver served as positive and negative control tissues, respectively, for the effects of DES on IGF-I mRNA levels in OVX rats; mRNA levels were increased in uterus and decreased in liver after hormone treatment. We conclude from these studies that estrogen reduces periosteal bone formation by inhibiting both the differentiation and activity of osteoblasts. Furthermore, down-regulation of mRNA levels for IGF-I and bone matrix proteins precedes the changes in dynamic bone histomorphometry.

AB - Dynamic bone histomorphometry, [3H]thymidine radioautography, and Northern analysis for bone matrix proteins and insulin-like growth factor-I (IGF-I) were performed in calvariae of ovariectomized (OVX) and estrogen-treated OVX rats. Treatment of OVX rats with diethylstilbestrol (DES) for 2 weeks reduced the periosteal mineral apposition rate, osteoblast number, and osteoblast size in calvarial periosteum. DES treatment also reduced the number of preosteoblasts in the S phase of the cell cycle, suggesting that the decrease in osteoblast number was due in part to inhibition of proliferation of osteoprogenitor cells. One week after ovariectomy, there were small increases in mRNA levels for pre pro-α2 (I) subunit of type I collagen (collagen), ostcocalein, and osteonectin and a large increase in the mRNA level for IGF-I. DES treatment resulted in rapid decreases (3 h) in the mRNA levels for osteonectin, osteocalcin, and IGF-I. In contrast, mRNA levels for collagen were virtually unchanged after short term DES treatment. Uterus and liver served as positive and negative control tissues, respectively, for the effects of DES on IGF-I mRNA levels in OVX rats; mRNA levels were increased in uterus and decreased in liver after hormone treatment. We conclude from these studies that estrogen reduces periosteal bone formation by inhibiting both the differentiation and activity of osteoblasts. Furthermore, down-regulation of mRNA levels for IGF-I and bone matrix proteins precedes the changes in dynamic bone histomorphometry.

UR - http://www.scopus.com/inward/record.url?scp=0026671788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026671788&partnerID=8YFLogxK

M3 - Article

VL - 131

SP - 883

EP - 889

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 2

ER -